Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424598 | 0.84 | CNR2 (0.35) | MAPTALDH1A1KMT2AGAA | |
| SCHEMBL12424646 | 0.81 | SCN9A (0.33) | SCN9AGABRA1GABRB2ALDH1A1HSP90AA1 | |
| SCHEMBL12424663 | 0.81 | HSP90AA1 (0.31) | SCN9AGABRA1GABRB2HSP90AA1 | |
| SCHEMBL3920058 | 0.80 | PDK2 (0.36) | MAPTALDH1A1KMT2AGAA | |
| SCHEMBL12424664 | 0.76 | HSP90AA1 (0.35) | MAPTALDH1A1HSP90AA1MEN1KMT2A | |
| SCHEMBL10018217 | 0.75 | HSP90AA1 (0.37) | MAPTALDH1A1HSP90AA1MEN1KMT2A | |
| SCHEMBL12424667 | 0.75 | AURKA (0.34) | MAPTALDH1A1HSP90AA1MEN1KMT2A | |
| SCHEMBL3924406 | 0.73 | ALDH1A1 (0.39) | MAPTALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7322958 | 0.73 | CYP1A2 (0.45) | KMT2A | |
| SCHEMBL25836768 | 0.72 | HSP90AA1 (0.36) | MAPTALDH1A1HSP90AA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2055698-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2055698-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100230649-A1 | CHROMENE COMPOUND | CCNT1, RB1, H1-0 | SCN9A 1556/4885GABRA1 3983/4885GABRB2 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.